What type of study is this?

December 4, 2025Breast Cancer Basic and Clinical ResearchOpen Access

Evaluation of Recurrence Rate in Canadian Patients With Stage II/III HR+/HER2− Early Breast Cancer in the Real-World Setting

View Full Paper

Ask AI

Bookmark

Recurrence rates in the adjuvant setting peaked at 58.4% after 10 years, indicating significant challenges for patients treated with adjuvant therapy.
The cohort of 541 patients showed a preference for adjuvant treatment using endocrine therapy combined with cytotoxic agents, particularly in stage III cases.
Neoadjuvant therapy involving cytotoxic agents was more common in stage III patients, with many continuing on to adjuvant treatment.
This analysis emphasizes a pressing need for better treatment strategies for reducing recurrence in HR+/HER2− breast cancer patients.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Retrospective analysis found high recurrence rates in Canadian patients with early HR+/HER2− breast cancer, highlighting the need for improved treatment options.

Cite This Study

Gambaro et al. (2025) studied this question.

synapsesocial.com/papers/6930dc9eea1aef094cca2d8f https://doi.org/10.1177/11782234251395892

View Full Paper

Ask AI

Bookmark

Implication

Retrospective analysis found high recurrence rates in Canadian patients with early HR+/HER2− breast cancer, highlighting the need for improved treatment options.

Evaluation of Recurrence Rate in Canadian Patients With Stage II/III HR+/HER2− Early Breast Cancer in the Real-World Setting

Key Points

Discussion

Implication

Cite This Study

Evaluation of Recurrence Rate in Canadian Patients With Stage II/III HR+/HER2− Early Breast Cancer in the Real-World Setting

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider